Stockscreener 앱 받기
2.125
3.16%
0.065
전일 마감가:
$2.06
열려 있는:
$2.08
하루 거래량:
780.72K
Relative Volume:
0.55
시가총액:
$285.95M
수익:
-
순이익/손실:
$-101.70M
주가수익비율:
-1.1207
EPS:
-1.8961
순현금흐름:
$-84.35M
1주 성능:
+2.66%
1개월 성능:
+45.55%
6개월 성능:
+57.41%
1년 성능:
+327.57%
1일 변동 폭
$2.00
$2.17
1주일 범위
$2.00
$2.41
52주 변동 폭
$0.444
$2.66
AIx 온콜로지 Stock (ALXO) Company Profile
명칭
Alx Oncology Holdings Inc
전화
650-466-7125
주소
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
2.125 | 285.95M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIx 온콜로지 Stock (ALXO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-19 | 개시 | Wells Fargo | Overweight |
| 2026-03-06 | 재개 | UBS | Buy |
| 2025-11-13 | 개시 | Jefferies | Buy |
| 2025-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-06 | 개시 | UBS | Buy |
| 2021-02-10 | 개시 | H.C. Wainwright | Buy |
| 2020-08-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 개시 | Credit Suisse | Outperform |
| 2020-08-11 | 개시 | Jefferies | Buy |
| 2020-08-11 | 개시 | Piper Sandler | Overweight |
모두보기
AIx 온콜로지 주식(ALXO)의 최신 뉴스
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - The Globe and Mail
ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations - Stock Titan
ALXOAlx Oncology Holdings Inc Options - Finviz
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times
ALX Oncology Appoints New Chairman Amid Leadership Changes - TipRanks
ALX Oncology grants 500,000-share option to new general counsel - Stock Titan
ALX Oncology's Corey Goodman resigns as Chairman and director - TradingView
Leadership shifts at ALX Oncology (NASDAQ: ALXO) as Garland becomes chair - Stock Titan
ALX Oncology names Scott Garland chairman, adds general counsel - Investing.com UK
ALX Oncology names Scott Garland chairman, adds general counsel By Investing.com - Investing.com India
ALXO Welcomes New Leadership with Board Changes - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel - Investing News Network
ALX Oncology appoints Scott Garland as chairman and Michael Listgarten as general counsel to strengthen leadership - Traders Union
ALX Oncology replaces its chairman and adds a new general counsel - Stock Titan
ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2500 Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2000 Index - marketscreener.com
ALX Oncology Holdings Inc. (ALXO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2000 Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 3000E Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell Microcap Index - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 3000E Index - marketscreener.com
ALXO Stock Edges Higher As Jefferies Conference Spotlights Oncology Pipeline - timothysykes.com
ALXO Rises As ALX Oncology Showcases Pipeline At Jefferies - StocksToTrade
Price to sales forward of ALX Oncology Holdings Inc. – NASDAQ:ALXO - TradingView
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2000 Dynamic Index - marketscreener.com
ALX Oncology Secures New $50 Million Loan Facility - The Globe and Mail
Alx Oncology HoldingsEnters Loan And Security Agreement With HSBC Ventures On June 25, 2026SEC Filing - TradingView
ALX Oncology (NASDAQ: ALXO) adds up to $50M secured loan facility - Stock Titan
ALX Oncology Holdings, Inc. Actuals & Estimates (NASDAQ:ALXO) - TradingView
ALXO Forecast — Price Target — Prediction for 2027 - TradingView
ALX Oncology Holdings Inc (ALXO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ALX Oncology: Rebuilding From Critical Setbacks (NASDAQ:ALXO) - Seeking Alpha
ALXO News | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALX Oncology Holdings Inc (ALXO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALX Oncology Holdings Inc (ALXO) Valuation: PE, PB & Fair Value Analysis - TradingKey
ALX Oncology Holdings Inc (ALXO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ALX Oncology Holdings Inc (ALXO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ALX Oncology Holdings Inc (ALXO) Institutional Confidence - TradingKey
ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALXO Q1 2026 Earnings: EPS Beat Amid Pre‑Revenue Development StageMargin Guidance - newsline.com
ALX Oncology (ALXO) Edges Higher: Near-Term Support and Resistance in FocusLow Volume Node - newsline.com
ALXO Q1 2026 Earnings: EPS Surprise of 26.23% Highlights Cost Discipline Amid Clinical ProgressRevenue Recognition Risk - newsline.com
ALXO Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares HigherEarnings Cycle Outlook - newsline.com
ALX Oncology Shareholders Approve Directors and Executive Pay - TipRanks
ALX Oncology (NASDAQ: ALXO) holders back board slate, executive pay and KPMG audit - Stock Titan
ALX Oncology targets key readouts to advance CD47, EGFR cancer drug programs - MSN
AIx 온콜로지 (ALXO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
AIx 온콜로지 주식 (ALXO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Mar 19 '26 |
Sale |
2.17 |
12,311 |
26,715 |
293,609 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Mar 19 '26 |
Sale |
2.17 |
903 |
1,960 |
86,805 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 18 '26 |
Sale |
2.27 |
565 |
1,283 |
87,708 |
| GOODMAN COREY S | Director |
Feb 02 '26 |
Buy |
1.57 |
3,184,713 |
4,999,999 |
8,453,038 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jan 06 '26 |
Sale |
1.11 |
3,925 |
4,357 |
88,273 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
2.64%
자본화:
|
볼륨(24시간):